CDC25A Antibody

Catalog No: #32202

Package Size: #32202-1 50ul #32202-2 100ul



Orders: order@signalwayantibody.com Support: tech@signalwayantibody.com


Description

Product Name	CDC25A Antibody
Host Species	Rabbit
Clonality	Polyclonal
Purification	Antibodies were purified by affinity purification using immunogen.
Applications	WB,IHC,IF
Species Reactivity	Human,Mouse,Rat
Specificity	The antibody detects endogenous level of total CDC25A protein.
Immunogen Type	Recombinant Protein
Immunogen Description	Recombinant protein of human CDC25A.
Target Name	CDC25A
Other Names	CDC25A2; CDC25A; cdc25A;
Accession No.	Swiss-Prot:P30304NCBI Gene ID:993
SDS-PAGE MW	59KD
Concentration	1.0mg/ml
Formulation	Supplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02%
	sodium azide and 50% glycerol.
Storage	Store at -20°C


Application Details

WB 1:500 - 1:2000IHC 1:50 - 1:200IF 1:50 - 1:200

Images



Immunofluorescence analysis of HeLa cells using CDC25A Polyclonal antibody at dilution of 1:100 (40x lens). Blue: DAPI for nuclear staining.



Background

The cdc25 protein phosphatase family plays a critical role in activating cyclin-dependent kinases (CDKs) via dephosphorylation of conserved Thr14/Tyr15 inhibitory phosphorylation sites. While cdc25C is primarily responsible for activating CDK1 to overcome the G2/M checkpoint and allow mitotic entry, the primary substrate of cdc25A is CDK2, which, when active, allows progression through the G1/S and intra-S checkpoints (1). Abundance, subcellular localization and activity of cdc25A is tightly controlled by a variety of mechanisms, including phosphorylation, ubiquitination, and inhibitory binding to 14-3-3 proteins. During normal cell cycle progression, elevated c-Myc and E2F transcription factor levels lead to increased cdc25A expression (2). When conditions are favorable for DNA synthesis, cdc25A and CDK2 form an activation loop, wherein each activates the other enzyme (1). DNA damage, on the other hand, leads to multisite phosphorylation at inhibitory sites (Ser123, Ser177, Ser278, Ser292, and Thr506) by Chk1 and Chk2, which result in 14-3-3 binding and ubiquitin-mediated degradation (3,4).

Published Papers

el at., Dub3 expression correlates with tumor progression and poor prognosis in human epithelial ovarian cancer.In Biomed Pharmacother on 2015 Mar by Bo Zhou , Bin Shu et al..PMID:25776484, , (2015) PMID:25776484

Note: This product is for in vitro research use only and is not intended for use in humans or animals.